Infrared Laser Therapy for Ischemic Stroke: A New Treatment Strategy

Abstract

Background and Purpose-The NeuroThera Effectiveness and Safety Trial-1 (NEST-1) study evaluated the safety and preliminary effectiveness of the NeuroThera Laser System in the ability to improve 90-day outcomes in ischemic stroke patients treated within 24 hours from stroke onset. The NeuroThera Laser System therapeutic approach involves use of infrared laser technology and has shown significant and sustained beneficial effects in animal models of ischemic stroke. Methods-This was a prospective, intention-to-treat, multicenter, international, double-blind, trial involving 120 ischemic stroke patients treated, randomized 2:1 ratio, with 79 patients in the active treatment group and 41 in the sham (placebo) control group. Only patients with baseline stroke severity measured by National Institutes of Health Stroke Scale (NIHSS) scores of 7 to 22 were included. Patients who received tissue plasminogen activator were excluded. Outcome measures were the patients' scores on the NIHSS, modified Rankin Scale (mRS), Barthel Index, and Glasgow Outcome Scale at 90 days after treatment. The primary outcome measure, prospectively identified, was successful treatment, documented by NIHSS. This was defined as a complete recovery at day 90 (NIHSS 0 to 1), or a decrease in NIHSS score of at least 9 points (day 90 versus baseline), and was tested as a binary measure (bNIH). Secondary outcome measures included mRS, Barthel Index, and Glasgow Outcome Scale. Primary statistical analyses were performed with the Cochran-Mantel-Haenszel rank test, stratified by baseline NIHSS score or by time to treatment for the bNIH and mRS. Logistic regression analyses were conducted to confirm the results. Results-Mean time to treatment was Ͼ16 hours (median time to treatment 18 hours for active and 17 hours for control).Time to treatment ranged from 2 to 24 hours. More patients (70%) in the active treatment group had successful outcomes than did controls (51%), as measured prospectively on the bNIH (Pϭ0.035 stratified by severity and time to treatment; Pϭ0.048 stratified only by severity). Similarly, more patients (59%) had successful outcomes than did controls (44%) as measured at 90 days as a binary mRS score of 0 to 2 (Pϭ0.034 stratified by severity and time to treatment; Pϭ0.043 stratified only by severity). Also, more patients in the active treatment group had successful outcomes than controls as measured by the change in mean NIHSS score from baseline to 90 days (Pϭ0.021 stratified by time to treatment) and the full mRS ("shift in Rankin") score (Pϭ0.020 stratified by severity and time to treatment; Pϭ0.026 stratified only by severity). The prevalence odds ratio for bNIH was 1.40 (95% CI, 1.01 to 1.93) and for binary mRS was 1.38 (95% CI, 1.03 to 1.83), controlling for baseline severity. Similar results held for the Barthel Index and Glasgow Outcome Scale. Mortality rates and serious adverse events (SAEs) did not differ significantly (8.9% and 25.3% for active 9.8% and 36.6% for control, respectively, for mortality and SAEs). Conclusion-The NE...

The in-depth evaluation of suspected mitochondrial disease

“…Today, specific wavelengths in the red and near infrared ranges (ca 600-1200 nm) are known to stimulate a wide array of biological processes ranging from the expansion of cardiac stem cells in culture [148] to accelerated healing of chemotherapy-associated mucositis [149]. Low level laser treatment using an 808 nm light source has even shown promise in a blinded, prospective clinical trial in acute stroke patients [150].…”

Photobiomodulation inside the brain: a novel method of applying near-infrared light intracranially and its impact on dopaminergic cell survival in MPTP-treated mice

“…It is one thing for NIr to influence SNc survival 4-5 mm inside the skull of a mouse, and quite another to reliably influence SNc survival 80-100 mm inside the skull of a human. Indeed, almost all current clinical studies reporting the beneficial effects of NIr treatment have involved cases in which the target region was in the cortex, lying only 8-10 mm below the cranium, 19 whether in patients suffering trauma, 27 stroke, 17,19 or depression. 36 Structures lying much deeper in the human brain, such as in the SNc, may be largely beyond the range of externally applied NIr.…”

Transcranial low-level laser therapy may improve alertness and awareness in traumatic brain injured subjects with severe disorders of consciousness: a case series

“…[8,14] Positive sham-controlled studies in acute stroke patients included the single T-LLT stimulation of 20 points according to the 10-20 system for one minute each, the wave length was 808 nm and the intensity 10 mW/cm 2 . [15,16,17] In embolized rabbit's brain, Lapchak and De Taboada successfully showed that T-LLT (wave length 808 nm, intensity 10 mW/cm 2 ) significantly increased the cortical ATP, the penetration depth was 20 -30 mm. [18] Accordingly the authors of the acute stroke studies speculated that the transcranial laser could have activated the respiratory chain, namely the complex IV, thus increasing the ATP production and helping cell recuperation.…”